Von Willebrand factor in high‐purity factor VIII complex concentrates: chaperone protein or key to therapies? A meeting report

A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM‐1 VWD)

2006 • 510 citations

Treatment of von Willebrand's Disease

2004 • 483 citations

Recombinant Factor VIII for the Treatment of Previously Untreated Patients with Hemophilia A -- Safety, Efficacy, and Development of Inhibitors

1993 • 482 citations

Von Willebrand disease type 1: a diagnosis in search of a disease

2003 • 305 citations

Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A

2005 • 300 citations

The North American Immune Tolerance Registry: Practices, Outcomes, Outcome Predictors

2002 • 269 citations

The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977–99

2004 • 266 citations

Polymorphisms in the IL10 but not in the IL1beta and IL4 genes are associated with inhibitor development in patients with hemophilia A

2005 • 258 citations

Immune Tolerance for the Treatment of Factor VIII Inhibitors ‐ Twenty Years' ‘Bonn Protocol’

1996 • 228 citations

Polymorphisms in the TNFA gene and the risk of inhibitor development in patients with hemophilia A

2006 • 214 citations

The Malmö International Brother Study (MIBS): further support for genetic predisposition to inhibitor development

2001 • 202 citations

VWF protects FVIII from endocytosis by dendritic cells and subsequent presentation to immune effectors

2006 • 187 citations

Intensive exposure to factor VIII is a risk factor for inhibitor development in mild hemophilia A

2003 • 185 citations

Recombinant Factor VIII for the Treatment of Previously Untreated Patients with Hemophilia A

1993 • 183 citations

Incidence of factor VIII inhibitors in severe haemophilia: the importance of patient age

2001 • 178 citations

BIOLOGY AND GENETICS OF PRION DISEASES

1994 • 170 citations

Early factor VIII exposure and subsequent inhibitor development in children with severe haemophilia A

2007 • 168 citations

Environmental and genetic factors influencing inhibitor development

2004 • 163 citations

Bovine spongiform encephalopathy (BSE) and its epidemiology

2003 • 144 citations

Treatment characteristics and the risk of inhibitor development: a multicenter cohort study among previously untreated patients with severe hemophilia A

2007 • 143 citations

Long-term prophylaxis in von Willebrand disease

2005 • 112 citations

The factor VIII/von Willebrand factor complex: basic and clinical issues.

2003 • 108 citations

Immune tolerance induction in patients with haemophilia A with inhibitors: a systematic review

2003 • 104 citations

Von Willebrand Factor Modulates Factor VIII Immunogenicity: Comparative Study of Different Factor VIII Concentrates in a Haemophilia A Mouse Model

2002 • 103 citations

Variant Creutzfeldt–Jakob disease: risk of transmission by blood transfusion and blood therapies

2006 • 88 citations

The role of plasma-derived factor VIII/von Willebrand factor concentrates in the treatment of hemophilia A patients.

2003 • 82 citations

Immune tolerance induction with a high purity von Willebrand factor/VIII complex concentrate in haemophilia A patients with inhibitors at high risk of a poor response

2007 • 81 citations

International Immune Tolerance Registry, 1997 Update

1999 • 59 citations

Inhibitor Development in Patients with Hemophilia A after Continuous Infusion of FVIII Concentrates

2005 • 56 citations

Impact of inhibitor epitope profile on the neutralizing effect against plasma‐derived and recombinant factor VIII concentrates in vitro

2003 • 48 citations

Relationships between factor VIII:Ag and factor VIII in recombinant and plasma‐derived factor VIII concentrates

2004 • 48 citations

von Willebrand factor in factor VIII concentrates protects against neutralization by factor VIII antibodies of haemophilia A patients

2001 • 48 citations

Impact of different inhibitor reactivities with commercial factor VIII concentrates on thrombin generation

2006 • 41 citations

Peripheral arterial disease as global vascular risk factor.

2001 • 40 citations

Ristocetin Cofactor and Collagen Binding Activities Normalized to Antigen Levels for a Rapid Diagnosis of Type 2 von Willebrand Disease

2000 • 32 citations

von Willebrand factor in factor VIII concentrates protects against neutralization by factor VIII antibodies of haemophilia A patients

2001 • 30 citations

Immune Tolerance and the Immune Modulation Protocol

1996 • 21 citations

The evolving classification of von Willebrand disease

2005 • 20 citations

Molecular Aspects of Disease Pathogenesis in the Transmissible Spongiform Encephalopathies

2004 • 18 citations

Secondary long-term prophylaxis in von Willebrand disease: an Italian cohort study

2009 • 10 citations

Protective effect of prophylaxis on inhibitor development in children with haemophilia A: more convincing studies are required. Response to Calvez and Laurian

2006 • 5 citations